Метастатический или местно-рецидивирующий, неоперабельный рак молочной железы с опухолевой гиперэкспрессией HER2: в комбинации с трастузумабом и доцетакселом при отсутствии ранее проводимого лечения или при прогрессировании заболевания после проведения адъювантной терапии.

PERTUZUMAB

PERJETA is indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2 positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.Perjeta is indicated for use in combination with trastuzumab and docetaxel for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on demonstration of an improvement in pathological complete response rate. No data are available demonstrating improvement in event-free survival or overall.Limitations of Use:• The safety of Perjeta as part of a doxorubicin-containing regimen has not been established.• The safety of Perjeta administered for greater than 6 cycles for early breast cancer has not been established.